The sleep electroencephalogram (EEG) is highly heritable in humans and yet little is known about the genetic basis of inter-individual differences in sleep architecture. The aim of this study was to identify associations between candidate circadian gene variants and the polysomnogram, recorded under highly controlled laboratory conditions during a baseline, overnight, 8 h sleep opportunity. A candidate gene approach was employed to analyze single-nucleotide polymorphisms from five circadian-related genes in a two-phase analysis of 84 healthy young adults (28 F; 23.21 ± 2.97 years) of European ancestry. A common variant in Period2 (PER2) was associated with 20 min less slow-wave sleep (SWS) in carriers of the minor allele than in noncarriers, representing a 22% reduction in SWS duration. Moreover, spectral analysis in a subset of participants (n = 37) showed the same PER2 polymorphism was associated with reduced EEG power density in the low delta range (0.25-1.0 Hz) during non-REM sleep and lower slow-wave activity (0.75-4.5 Hz) in the early part of the sleep episode. These results indicate the involvement of PER2 in the homeostatic process of sleep. Additionally, a rare variant in Melatonin Receptor 1B was associated with longer REM sleep latency, with minor allele carriers exhibiting an average of 65 min (87%) longer latency from sleep onset to REM sleep, compared to noncarriers. These findings suggest that circadianrelated genes can modulate sleep architecture and the sleep EEG, including specific parameters previously implicated in the homeostatic regulation of sleep.
Introduction
Sleep is regulated by two main physiological processes: (1) the circadian timing system (process C), regulating daily rhythms of sleep and wakefulness; and (2) the sleep homeostatic process (process S), which tracks accumulating sleep pressure with time awake and which decreases with time asleep (Borbély, 1982) . The prevalence and amplitude of slow waves in the sleep electroencephalogram (EEG), typically quantified by slow-wave activity (SWA; 0.75-4.5 Hz power density) or slow-wave sleep (SWS), serve as markers of homeostatic sleep pressure (Achermann et al., 1993) . The EEG is highly heritable, both during wakefulness (h 2 = 76-89%) (Lennox et al., 1945; van Beijsterveldt & van Baal, 2002 ) and during sleep (h 2 = 50-96%) (Ambrosius et al., 2008; Landolt & Dijk, 2010; Linkowski, 1999) . Surprisingly, despite the high heritability of EEG traits, little is known about the genetic basis of these inter-individual differences in the sleep EEG.
Several sleep-associated genetic variants have been identified in human candidate-gene studies but associations have not been consistently reproduced; namely in PER3, DQB1*0602, ADA, ADORA2A, BDNF and COMT (Bachmann et al., 2012; Bodenmann et al., 2012; Bodenmann & Landolt, 2010; Guindalini et al., 2014; Mignot et al., 1999; Retey et al., 2005; Viola et al., 2007) . Of these genes, however, only PER3 is considered a genetic component of the circadian molecular timing system shown to alter the sleep EEG in humans (Viola et al., 2007) . Gene variants in BDNF, a circadian-related gene, have also been implicated in changes to EEG during sleep (Bollen & Curran, 2005; Guindalini et al., 2014 ).
In the current study, we used a candidate gene approach to identify associations between singlenucleotide polymorphisms (SNPs) in circadianrelated genes and polysomnographic (PSG) measures collected under controlled laboratory conditions, an ideal setting for reducing environmental and behavioral variation to identify genetic variants with a strong effect. Common SNPs in five circadian-related genes were genotyped in our laboratory sample: Circadian Locomotor Output Cycles Kaput (CLOCK), Cryptochrome2 (CRY2), basic helix-loop-helix family, member e41 (BHLHE41; or DEC2), Period2 (PER2) and Melatonin Receptor1B (MTNR1B). As an initial exploration of the role of circadian genes in sleep physiology, we selected these genes as candidates based on: (1) previously reported associations with sleep phenotypes in the case of CLOCK, DEC2 and PER2 (Allebrandt et al., 2010; He et al., 2009; Toh et al., 2001) ; and (2) association with type 2 diabetes (T2D) risk (Dupuis et al., 2010; Lyssenko et al., 2008; Prokopenko et al., 2008) , in the case of CRY2 and MTNR1B. Furthermore, MTNR1B gene variants were included in this analysis because of previously documented association with metabolic measures (Dupuis et al., 2010; Lyssenko et al., 2008; Prokopenko et al., 2008) and its role as an output of the clock, not because of a role in the core molecular clock. Because sleep disturbances and short sleep duration lead to increased risk of T2D (Nedeltcheva & Scheer, 2014; Spiegel et al., 2005) , we hypothesized that changes in sleep quality and/or duration may provide a mechanistic link between known variants in this gene and T2D risk (Hanlon & Van Cauter, 2011) .
Methods

Overview
This genetic study includes data from individuals who previously participated in one of several inpatient physiological protocols in which their sleep EEG was recorded in the Intensive Physiological Monitoring Unit of the Brigham and Women's Hospital. Written informed consents, both for the original in-laboratory studies and for the genetic studies, were obtained from each study participant. The Partners Human Research Committee approved the protocol and study procedures conformed to the Declaration of Helsinki.
Study participants and screening procedures
A total of 101 healthy adults aged 18-35 years (34 F; mean age ± SD 23.10 ± 3.28 years) were enrolled in this study. A PSG recording collected during an 8 h baseline overnight sleep episode (first or third night; see below; Figure 1 ) and genetic samples obtained from each participant were used for association analyses.
Prior to admission, study participants completed extensive screening procedures to ensure eligibility. Inclusion criteria required that participants were 18-35 years of age and in good health, free from medical or psychological conditions or disorders. While the protocols in which the volunteers participated varied slightly from each other with respect to specific screening procedures, all protocols included a physical examination, laboratory tests of blood and urine samples, a 12-lead electrocardiogram (ECG), and an interview with a clinical psychologist to confirm good medical and psychological health. Exclusion criteria included night work in the prior 3 years and travel across >1 time zone in the prior 3 months. During the 3-week pre-admission screening interval, participants were asked to refrain from taking medications, alcohol, caffeine and nicotine; and they maintained a self-selected, stable, 8 h sleep schedule each night, which was verified with daily sleep diaries, time-stamped telephone calls at bedtime and wake time, and wrist actigraphy for a minimum of 1 week prior to admission.
Genotyping
DNA was extracted from whole blood using Qiagen Autopure LS (Qiagen, Limburg, The Netherlands). A total of 116 SNPs tagging common variation and rare missense variants from the five candidate genes (CLOCK, CRY2, BHLHE41, PER2 and MTNR1B; ±20 kb) were selected, providing full coverage for each gene (see supplemen tary table 1 for full list). SNPs with a minor allele frequency (MAF) > 0.05 were selected using a pairwise tagging threshold (r 2 > 0.8) in four populations: Northern and Western European (CEU), Yoruba African (YRI), Han Chinese (CHB) and Japanese (JPT) in HapMap release 21 in Tagger on Haploview (Barrett et al., 2005) . Additionally, 58 African-American and Hispanic ancestry informative markers were genotyped to test and correct for population stratification. Genotyping was performed using the Sequenom platform (Broad Institute, Cambridge, MA).
Standard quality control criteria included SNP genotyping rate > 90%, MAF > 1% and HardyWeinberg equilibrium (HWE) p > 10 −6 and were assessed using PLINK (Purcell et al., 2007) . Also, 11 SNPs were excluded due to low genotyping rate, 20 SNPs were excluded due to low MAF and 3 SNPs were excluded on the basis of departure from HWE; several of the SNPs were excluded by more than one criterion leaving 87 SNPs that passed all quality control filters. For primary association analysis, 84/101 participants that were genetically categorized as being of European ancestry (within 4 SD of the HapMap release 3 CEU panel based on principal components analysis) were selected (see supplementary figure 1 ).
PSG recordings and sleep measures
PSG recordings were continuously monitored and recorded throughout an 8 h baseline sleep episode using a Vitaport-3 recording system (TEMEC Instruments, B.V. Kerkrade, The Netherlands). Recordings included the EEG (derivations C3, C4, O1 and O2, referenced to contralateral mastoids), right and left electrooculogram, electromyogram and the ECG. Electrode impedances were <10 kΩ prior to the beginning of each recording. EEG signals were filtered (high-pass EEG filter 0.23 Hz; low-pass EEG filter 70.1 Hz; 24 dB/octave, sampling rate 256 Hz). PSG records were scored (blind to genotype) visually in 30 s epochs according to conventional criteria of Rechtschaffen and Kales (1968) . Sleep measures included total sleep time (TST); sleep efficiency (TST/time in bed as a %); sleep latency (interval between lights off and first stage of sleep); duration for stage 1, stage 2, and SWS (SWS; stages 3 and 4 combined), REM (rapid eye movement) sleep and wakefulness; wake after sleep onset (WASO); wake after final awakening (WAFA); and number of awakenings longer than 30 s. Duration of sleep stages and wakefulness was calculated in minutes. For sleep stage 2, SWS and REM (rapid eye movement) sleep, latencies were computed from sleep onset. PSG measures that were not normally distributed were transformed to achieve a normal distribution, including SWS duration and number of awakenings (log transformation) and REM sleep latency (inverse normal transformation).
Spectral analysis of C3/A2 EEG recordings was also completed in the subset of male participants whose PSG was recorded on the third baseline night (n = 37; see below). Signals were first visually inspected, and 4 s epochs containing artifacts arising from body movements, eye blinks or eye movements were removed. The remaining 4 s epochs were subjected to fast Fourier transformation, using a 10%-cosine-tapered window (Vitascore, TEMEC, The Netherlands). A maximum of 10 consecutive, overlapping 4 s epochs were averaged into 30 s epochs and matched with sleep scores. Data were reduced further by averaging power densities into 0.5 Hz bins. For a specific SNP that was associated with SWS, power spectra were compared between genotype groups (risk-allele carriers vs. noncarriers) by ANOVA (SAS 9.2, SAS Institute Inc., Cary, NC, USA).
Genetic analysis and protocol groups
Genetic analysis was initiated in a cohort in whom PSG was recorded during the 8 h sleep episode on the third baseline night (phase 1; n = 59; Figure 1a ). Potential associations with significance (p < 0.001) were then tested in a separate cohort of different individuals in whom PSG recordings were collected during the 8 h sleep episode on the first baseline night in the laboratory (phase 2; n = 25; Figure 1b) . Procedures for the collection of PSG, sleep schedule, room conditions and ambient light levels prior to the sleep episode were consistent between phase 1 and 2 cohorts. Both groups were independent with no overlap of individuals, and the cohorts were selected a priori. The phase 2 group in which PSG was collected during the first baseline night was selected to provide a more stringent test of replication for any potential associations that were identified in the phase 1 cohort, assuming greater variability in measures due to first-night effects.
An additive genetic model was used to test for association of SNPs with sleep measures in linear regression analyses. All analysis presented was adjusted for covariates age, sex and ancestry (five principal components). Permutation testing was used to evaluate significance after correction for multiple comparisons. As power for single-variant association testing was low and individual effects may be subtle, an additional gene-based analysis was conducted using sequence kernel association testing (SKAT) to detect combined effects of variants (Ionita-Laza et al., 2013) . This analysis provides a more comprehensive view of potential associations between candidate genes and phenotypes by including all variants from one gene, rather than each individual SNP, in the analysis. Furthermore, this allowed for a reduced number of comparisons (the number of genes as opposed to the number of SNPs).
Results
Summary sleep measures for both cohorts are shown in Table 1 . The cohorts differed significantly only in REM sleep duration, with a shorter REM sleep duration in the phase 2 cohort, which may have been due to a first-night effect in that cohort (Agnew et al., 1966) . Results for SNPs most strongly associated with sleep phenotype measures in the phase 1 cohort, in the phase 2 cohort and from meta-analysis of the entire sample are listed in Table 2 . In phase 1, an SNP in the PER2 gene (rs6753456) showed a significant association with SWS duration; a second PER2 SNP (rs3739064) was associated with the number of awakenings; and a MTNR1B SNP (rs7942988) was associated with REM sleep latency. None of these associations remained significant in the smaller phase 2 cohort in which only first-night sleep data were assessed. Nonetheless, two associations remained significant in the meta-analysis of both phases of analysis: the PER2 SNP with SWS duration and the MTNR1B SNP with REM sleep latency. For the two phenotypes that showed significant association in the meta-analysis, the association with all tested SNPs is shown in supplementary figure 2; and association plots for remaining sleep phenotypes with all SNPs are shown in supplementary figure 3.
Results from association testing of the two sleepassociated SNPs with circadian phenotypes are shown in supplementary table 2.
PER2
A common polymorphism in the PER2 gene (rs6753456; MAF 38%) was significant in the phase 1 sample for SWS duration with 24 min less SWS in risk allele carriers compared to noncarriers, a difference of 27% (p = 9.2 × 10 −4 ; Table 2 ). While the magnitude of the effect of this PER2 SNP was similar in the phase 2 cohort (19 min less of SWS), this association was not statistically significant (p = 0.103). Meta-analysis of both phases showed association with 20 min of less SWS duration, equivalent to a 22% reduction compared to noncarriers (p = 4.43 × 10 −4 ). This difference was significant after correction for multiple comparisons (p adj = 0.046). Consistent results of a study-wide significant association (p = 3.39 × 10 −4 ) with no heterogeneity of genetic effect between the more controlled phase 1 cohort and the noisier phase 2 cohort (I 2 = 0%, p het = 0.49; (Han & Eskin, 2011) were seen using a modified random effect meta-analysis approach, indicating that the genetic signal was robust to differences between the data sets. Model-estimated mean differences ± SE for SWS duration for the phase 1, phase 2, and meta-analysis groups are shown in Figure 2a . Results from meta-analysis of both phase groups revealed lower SWS in homozygous and heterozygous groups compared to the nonrisk allele carriers (Figure 2a) . EEG spectral analysis was carried out in the 37 male participants from the phase 1 sample in order to eliminate heterogeneity by sex, given that SWS power density differs between men and women (Armitage, 1995; Dijk et al., 1989; Ehlers & Kupfer, 1997) and because there was a very unequal ratio of men to women in the genotype groups. Genotype affected the power spectrum during non-REM sleep in a frequency-specific manner (genotype × EEG frequency bin, p = 0.049; Figure 3a ). Post hoc analysis showed that this effect arose mainly from lower power density in the low delta range (0.25-1.0 Hz; p < 0.044, F-test) in individuals with one or two copies of the risk allele compared to noncarriers. Moreover, genotype affected the time course of the typical SWA decline across the night that is a measure of the decrease in homeostatic sleep pressure across the night. The biggest effects of genotype were observed in the first half of the night, with lower EEG SWA in the risk allele carriers and a shallower decline of SWA across the sleep episode in the carriers (Figure 3b ). EEG power spectra during REM sleep were not affected by genotype (data not shown).
Another common PER2 SNP (rs3739064; MAF 21.3%) showed notable association with the number of awakenings in the phase 1 cohort (p = 6.0 × 10 −4 ; Table 2 ). Minor allele homozygotes (G/G) had an average of eight fewer awakenings per night than either those with a single copy of the minor allele (G/A) or noncarriers (A/A). This association was not significant in the phase 2 sample and meta-analysis did not show significant association after correction of multiple comparisons (p = 0.013, p adj = 0.505).
MTNR1B
A SNP in the MTNR1B gene (rs7942988; MAF 3.7%) was significantly associated with REM sleep latency from sleep onset (p = 3.10 × 10 −4
; Table 2) in the phase 1 cohort. Individuals carrying the risk allele showed much longer latencies to REM sleep (by 81 min) than noncarriers, corresponding to a doubling of REM sleep latency (111% increase). This association was not significant in the phase 2 sample alone (p > 0.1), but significant (p = 4.14 × 10 −4 , p adj = 0.046; Table 2) in the overall sample, with the latency from sleep onset to REM sleep 65 min (87%) longer in carriers than in noncarriers. In a secondary meta-analysis assuming random effects and testing for heterogeneity, this association demonstrated a consistent effect between the phase 1 and phase 2 cohorts (p = 6.5 × 10 −3 , I 2 = 8.7%, p het = 0.30). The risk allele of rs7942988 (T) is relatively rare with an MAF of 3.7% in our population (6 T/C and 0 T/T individuals). The distribution of REM sleep latency values from both the phase 1 and phase 2 cohorts are plotted in supplementary figure 4 and show that half of the risk allele carriers had REM sleep latencies that were more than twice Figure 2 . Model-estimated mean differences by genotype for (a) PER2 SNP rs6753456 and SWS duration and (b) MTNR1B SNP rs7942988 and REM sleep latency. Model-estimated means are set to 0 min for each cohort and mean differences were adjusted for covariates. Mean difference, standard error (SE) and corresponding n for each genotype group are shown for homozygous (black bars) and heterozygous (gray bars) carriers for the risk allele and noncarriers (white bars).
as long as the group average (>120 min). Post hoc analysis found that genotype had a significant effect on the chance of having an REM sleep latency >120 min using both χ 2 analysis (OR = 8.79; CI = 1.48-52.07; p = 0.008) and Fisher's exact test (p = 0.015). Figure 2b displays the model-estimated mean differences for REM sleep latency in the phase 1 and phase 2 cohorts by genotype.
This same MTNR1B gene variant rs7942988 that associated with REM sleep latency had a significant association (p = 0.013 with the duration of melatonin secretion, calculated as the difference between the dim light melatonin onset (DLMO) and offset (DLMOff). Because melatonin was collected only in the phase 1 sample, there were only three individuals with this rare allele (T) who had melatonin phase assessments available, but they had a significantly reduced duration of nocturnal melatonin secretion by 1.33 h compared to noncarriers, corresponding to a 13.1% reduction (supplementary table 2). This association with the melatonin secretion duration remained significant after correcting for multiple testing of the three SNPs (p adj = 0.039). This SNP was also associated with an earlier diurnal preference (p = 0.041), although this association was no longer significant after correction for multiple testing of three SNPs.
Gene-based analysis
Results of SKAT gene-based analysis showed associations for BHLHE41 (DEC2) with the duration of REM sleep (p = 0.005), PER2 with SWS (p = 0.027) and MTNR1B with REM sleep latency (p = 0.028) in phase 1 cohort. Only the BHLHE41 association remained significantly associated with REM sleep duration after correcting for multiple comparisons (five genes; p adj = 0.01).
Discussion
Associations between single variants in two candidate genes and sleep PSG measures were identified in our phase 1 sample. Meta analyses also showed study-wide significant associations for PER2 SNP rs6753456 with SWS duration and MTNR1B SNP rs7942988 with REM sleep latency that withstood correction for multiple tests. Neither association was observed in the smaller phase 2 sample alone; however, similar effect estimates and concordant direction of the allelic effects were seen in both samples. While statistical power ranged from 83% to 89% (with α = 0.05) in the phase 2 sample to replicate the effect that was observed in the phase 1 sample, lack of replication may be due to "winner's curse" in the initial sample, the small size of the phase 2 sample, and/or less favorable/more noisy experimental conditions during which the PSG was recorded (first night in phase 2 cohort versus third night in phase 1 cohort). As expected for a "first-night" effect in the phase 2 cohort, during which sleep is typically more disturbed due to sleeping in an unfamiliar laboratory environment and PSG recordings for the first time, there was significantly less REM sleep in the phase 1 cohort (Agnew et al., 1966) . First-night effects in the phase 2 cohort therefore could have confounded associations with the SNPs. Indeed, we purposefully selected a "noisier" phase 2 cohort to perform a stringent validation of significant findings from the phase 1 cohort, reasoning that replication despite the increased instability of firstnight measurements would favor true associations over false positives. Replication in additional large studies with EEG measurements will be important to validate these associations. Our study identified a common variant of PER2 (rs6753456) that was significantly associated with decreased SWS duration in the combined analysis of both cohorts after correction for multiple comparisons and showed a large effect size (20 min reduction of SWS). This SNP (rs6753456) is located in the upstream promoter region of PER2, a core circadian clock gene, and is in strong linkage disequilibrium (r 2 = 0.8) in Europeans with rs11894491, a regulatory variant annotated with promoter and enhancer histone marks, DNAse hypersensitivity sites and polymerase II binding in multiple cell lines (Ward & Kellis, 2012) . However, these SNPs are uncorrelated to another PER2 SNP in the 5' untranslated region that was reported to be associated with diurnal preference (Carpen et al., 2005 ). In the current study, PER2 gene variant rs6753456 was not associated with diurnal preference or any other circadian phenotype, such as timing of sleep, as was seen with a rare PER2 missense mutation in a family with advanced sleep phase disorder (Toh et al., 2001) . A study in mice showed that the effects of an acute 6 h sleep deprivation on increasing PER2 expression were dependent on the time of day (Curie et al., 2013) . In that report, the authors suggest that PER2 acts as an integrator of both circadian and homeostatic signals. Our findings are consistent with a role of PER2 in homeostatic sleep regulation. First, the greatest genotype-dependent differences in power density were found in the low delta range of the non-REM sleep EEG, which is particularly sensitive to changes in homeostatic sleep pressure (Aeschbach et al., 1996) . Second, the differences in SWA were specifically seen during the early part of sleep, that is, a time when homeostatic sleep pressure and its manifestation in the EEG are typically highest. To further corroborate the potential role of circadian genes in homeostatic sleep regulation, it will be important to subject individuals with different genotypes to challenges of the homeostatic system (e.g. sleep deprivation).
The MTNR1B variant rs7942988 showed significant association with REM sleep latency. The low prevalence of this allele in our population may explain the lack of replication. Although only 6/84 individuals were carriers for the risk allele, the effect size was considerable (>1 h longer REM sleep latency) and half of the carriers displayed REM sleep latencies of more than 2 h (120 min), indicating a "skipped" first REM sleep episode. It is remarkable that three of the six minor allele carriers were in the small subgroup of nine individuals who displayed a long REM sleep latency, consistent with skipping the first REM sleep episode (see supple mentary figure 4). Post hoc analysis to test whether the chance for skipping of the first REM sleep episode was significantly affected by the genotype found a significant association using both χ 2 analysis and Fisher's exact test. Since REM sleep is the sleep state most influenced by circadian phase (Czeisler et al., 1980) and MTNR1B is expressed in the central circadian pacemaker, the suprachiasmatic nucleus (SCN) (Pandi-Perumal et al., 2008) , the association between an MTNR1B gene variant and REM sleep latency may indicate that MTNR1B function modulates the SCN control of REM sleep propensity. This would need to be determined in future studies. It is also notable that we observed a significant association with a circadian phenotype (1.33 h shorter duration of melatonin profile) and a nominally significant association with diurnal preference (see supplementary table 2).
Although it is not clear how longer REM sleep latency and shorter duration of melatonin secretion are related, these findings suggest a possible role for MTNR1B in the circadian regulation of sleep, specifically REM sleep. Interestingly, and consistent with such a potential relationship, REM sleep latency has been reported to be increased in tetraplegia patients with complete cervical spinal cord transection and abolished nighttime peak in circulating melatonin (Berlowitz et al., 2012; Scheer et al., 2006) . More recently, in a separate analysis, we have found that the MTNR1B variant, rs10830963, previously associated with increased fasting glucose levels and increased risk of T2D is associated with longer duration of elevated melatonin levels and a delay in circadian phase of melatonin offset in a similar inpatient sample as the one in this analysis (Lane et al., 2015) . The variant in the current study, rs7942988, is not itself associated with risk of T2D (http://dia gram-consortium.org) or in strong linkage disequilibrium with common or rare MTNR1B variants previously associated with T2D (Dupuis et al., 2010; Lyssenko et al., 2008; Prokopenko et al., 2008) .
Results of the gene-based analysis showed trends of these associations for the PER2 and MTNR1B variants with SWS duration and REM sleep latency, respectively. In addition, the genebased analysis showed a significant association in a third gene, BHLHE41, with REM sleep duration, which was not identified by the analysis of individual SNPs. A rare variant in this gene (also known as DEC2) was associated with shorter sleep duration in humans (hDEC2-P385R) and less sleep time in transgenic mice carrying this mutation as compared to controls (He et al., 2009 ). Furthermore, sleep deprivation studies of both transgenic hDEC2-P385R mice and Dec2 knockout mice showed slower recovery following sleep loss, indicating the importance of this gene in sleep regulation (He et al., 2009 ). We did not find this rare variant in our entire sample, not surprising given the very low frequency of this allele, and thus were not able to replicate this previously reported association. Taken together, however, our findings support the evidence that BHLHE41 plays a role in the genetic regulation of sleep.
The small sample size was a limitation of this study, and due to limited power in this sample, we examined relatively common variants. A small sample size in addition to an unequal male/female ratio in the genotype groups for PER2 SNP rs6753456 was a limitation for the EEG spectral analysis. It will be important to replicate these findings in large samples, especially for the rare MTNR1B variant. Given the low number of minor allele carriers for this variant (six) and the finding that three of these showed significantly longer REM sleep latencies, it is theoretically possible that skipping of the first REM sleep episode could have influenced assessment of SWS and SWA, measures of sleep homeostasis. We found no direct association between MTNR1B SNP rs7942988 and SWS, however, making it unlikely that carriers were under increased homeostatic sleep pressure. Additionally, we focused our primary analysis on a European subset of the sample in order to examine a homogeneous group. Another limitation was that we tested only a few candidate genes as opposed to a more comprehensive panel or GWAS, although this reduced our multiple-testing burden. Selection of candidate genes was partially based on previously reported associations with circadian rhythms (Toh et al., 2001) , sleep phenotypes (Allebrandt et al., 2010; He et al., 2009 ) and/or diabetes risk (Dupuis et al., 2010; Lyssenko et al., 2008; Prokopenko et al., 2008) ; however, our aim was full coverage of each candidate gene by tagged SNPs rather than only previously associated SNPs. Notably, we found associations with SNPs in two of the five genes selected for this study. These positive results are likely due to the use of the phenotypic measures that were collected under exceedingly wellcontrolled conditions in carefully screened participants and involved the application of consistent and stringent procedures for the collection and analysis of data across protocols. Further studies examining these and other circadian gene variants with sleep EEG collected under different conditions are needed for replication of our results to determine functional pathways and tissue specificity for gene expression and for identification of other genetic associations. 
